CLL-076 Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Clinical Lymphoma Myeloma and Leukemia（2024）
Key words
ibrutinib,chlorambucil,randomized clinical trial,outcomes,safety
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined